Kura Oncology's (KURA) Market Outperform Rating Reaffirmed at JMP Securities

JMP Securities reaffirmed their market outperform rating on shares of Kura Oncology (NASDAQ:KURA - Free Report) in a report published on Thursday morning,Benzinga reports. JMP Securities currently has a $28.00 price objective on the stock.

Other analysts have also issued research reports about the company. BTIG Research lowered Kura Oncology from a "buy" rating to a "neutral" rating in a report on Thursday. TD Cowen reissued a "buy" rating on shares of Kura Oncology in a research note on Thursday, November 21st. Bank of America dropped their price target on shares of Kura Oncology from $36.00 to $29.00 and set a "buy" rating for the company in a research note on Friday, November 22nd. Jefferies Financial Group reduced their price objective on shares of Kura Oncology from $32.00 to $28.00 and set a "buy" rating on the stock in a research report on Thursday, November 21st. Finally, HC Wainwright boosted their target price on Kura Oncology from $37.00 to $40.00 and gave the company a "buy" rating in a research report on Thursday. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $27.13.

Kura Oncology Price Performance

Shares of KURA traded up $0.14 during mid-day trading on Thursday, reaching $8.79. The stock had a trading volume of 1,103,976 shares, compared to its average volume of 1,885,880. Kura Oncology has a 12 month low of $6.98 and a 12 month high of $24.17. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. The firm has a market cap of $683.51 million, a price-to-earnings ratio of -3.72 and a beta of 0.78. The business has a fifty day moving average of $8.74 and a 200 day moving average of $14.95.

Kura Oncology (NASDAQ:KURA - Get Free Report) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($0.64) by $0.01. During the same quarter in the previous year, the firm posted ($0.50) earnings per share. Equities analysts predict that Kura Oncology will post -2.44 EPS for the current year.

Insider Transactions at Kura Oncology

In other Kura Oncology news, insider Mollie Leoni sold 4,963 shares of the business's stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $39,058.81. Following the sale, the insider now owns 88,253 shares of the company's stock, valued at $694,551.11. The trade was a 5.32 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Thomas James Doyle sold 4,949 shares of the business's stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $38,948.63. Following the completion of the sale, the senior vice president now owns 88,193 shares in the company, valued at $694,078.91. This represents a 5.31 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 12,255 shares of company stock valued at $100,739 over the last 90 days. 5.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. SG Americas Securities LLC acquired a new stake in shares of Kura Oncology in the fourth quarter valued at approximately $436,000. Moody Aldrich Partners LLC lifted its holdings in Kura Oncology by 42.3% in the fourth quarter. Moody Aldrich Partners LLC now owns 143,587 shares of the company's stock valued at $1,251,000 after acquiring an additional 42,712 shares during the period. Harbor Capital Advisors Inc. boosted its holdings in Kura Oncology by 4.4% during the fourth quarter. Harbor Capital Advisors Inc. now owns 49,371 shares of the company's stock worth $430,000 after buying an additional 2,076 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Kura Oncology by 0.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 409,241 shares of the company's stock worth $7,997,000 after acquiring an additional 3,092 shares during the period. Finally, Jennison Associates LLC purchased a new stake in shares of Kura Oncology in the 4th quarter worth about $623,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.